Supernus Pharmaceuticals annual operating cash flow
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Supernus Pharmaceuticals Operating Cash Flow Growth & History (SUPN)
Supernus Pharmaceuticals's operating cash flow was $47.3M for fiscal 2025.
View full Supernus Pharmaceuticals company overviewSupernus Pharmaceuticals annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $47.3M | −$124.6M | −72.47% |
| 2024 | 2024-12-31 | $172.0M | $60.9M | +54.79% |
| 2023 | 2023-12-31 | $111.1M | −$5.7M | −4.91% |
| 2022 | 2022-12-31 | $116.8M | −$10.3M | −8.10% |
| 2021 | 2021-12-31 | $127.1M | −$11.3M | −8.14% |
| 2020 | 2020-12-31 | $138.4M | −$4.7M | −3.30% |
| 2019 | 2019-12-31 | $143.1M | $14.1M | +10.96% |
| 2018 | 2018-12-31 | $129.0M | $14.3M | +12.51% |
| 2017 | 2017-12-31 | $114.6M | $47.8M | +71.59% |
| 2016 | 2016-12-31 | $66.8M | $32.3M | +93.52% |
| 2015 | 2015-12-31 | $34.5M | $59.0M | — |
| 2014 | 2014-12-31 | −$24.5M | $33.5M | — |
| 2013 | 2013-12-31 | −$57.9M | −$10.8M | — |
| 2012 | 2012-12-31 | −$47.2M | −$11.0M | — |
| 2011 | 2011-12-31 | −$36.2M | −$3.6M | — |
| 2010 | 2010-12-31 | −$32.5M | — | — |
Supernus Pharmaceuticals quarterly operating cash flow
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating cash flow | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$4.8M | −$63.3M | — |
| Q1 2026 | 2026-03-31 | $66.5M | $35.9M | +117.41% |
| Q4 2025 | 2025-12-31 | $19.9M | −$24.5M | −55.27% |
| Q3 2025 | 2025-09-30 | −$61.7M | −$115.2M | — |
| Q2 2025 | 2025-06-30 | $58.5M | $22.9M | +64.31% |
| Q1 2025 | 2025-03-31 | $30.6M | −$7.8M | −20.32% |
| Q4 2024 | 2024-12-31 | $44.4M | −$552,000 | −1.23% |
| Q3 2024 | 2024-09-30 | $53.5M | $17.6M | +49.18% |
| Q2 2024 | 2024-06-30 | $35.6M | $54.5M | — |
| Q1 2024 | 2024-03-31 | $38.4M | −$10.7M | −21.83% |
| Q4 2023 | 2023-12-31 | $45.0M | $17.4M | +63.10% |
| Q3 2023 | 2023-09-30 | $35.9M | $22.0M | +159.19% |
| Q2 2023 | 2023-06-30 | −$18.9M | −$90.0M | — |
| Q1 2023 | 2023-03-31 | $49.1M | $44.8M | +1041.93% |
| Q4 2022 | 2022-12-31 | $27.6M | −$21.2M | −43.47% |
| Q3 2022 | 2022-09-30 | $13.8M | $18.0M | — |
| Q2 2022 | 2022-06-30 | $71.1M | $24.8M | +53.69% |
| Q1 2022 | 2022-03-31 | $4.3M | −$31.9M | −88.12% |
| Q4 2021 | 2021-12-31 | $48.8M | $16.8M | +52.70% |
| Q3 2021 | 2021-09-30 | −$4.1M | −$9.7M | — |
| Q2 2021 | 2021-06-30 | $46.3M | −$45.7M | −49.68% |
| Q1 2021 | 2021-03-31 | $36.2M | $27.3M | +306.01% |
| Q4 2020 | 2020-12-31 | $31.9M | −$11.9M | −27.08% |
| Q3 2020 | 2020-09-30 | $5.6M | −$32.1M | −85.13% |
| Q2 2020 | 2020-06-30 | $92.0M | $63.3M | +220.53% |
| Q1 2020 | 2020-03-31 | $8.9M | −$24.1M | −72.98% |
| Q4 2019 | 2019-12-31 | $43.8M | $10.9M | +33.31% |
| Q3 2019 | 2019-09-30 | $37.7M | −$24.8M | −39.70% |
| Q2 2019 | 2019-06-30 | $28.7M | $22.1M | +337.57% |
| Q1 2019 | 2019-03-31 | $33.0M | $5.9M | +21.60% |
| Q4 2018 | 2018-12-31 | $32.8M | −$3.5M | −9.59% |
| Q3 2018 | 2018-09-30 | $62.4M | $23.4M | +60.10% |
| Q2 2018 | 2018-06-30 | $6.6M | −$19.4M | −74.73% |
| Q1 2018 | 2018-03-31 | $27.1M | $13.8M | +103.12% |
| Q4 2017 | 2017-12-31 | $36.3M | $11.4M | +45.70% |
| Q3 2017 | 2017-09-30 | $39.0M | $10.8M | +38.12% |
| Q2 2017 | 2017-06-30 | $25.9M | $9.2M | +54.63% |
| Q1 2017 | 2017-03-31 | $13.4M | $16.5M | — |
| Q4 2016 | 2016-12-31 | $24.9M | $5.0M | +25.15% |
| Q3 2016 | 2016-09-30 | $28.2M | $28.8M | — |
| Q2 2016 | 2016-06-30 | $16.8M | $2.1M | +14.37% |
| Q1 2016 | 2016-03-31 | −$3.1M | −$3.6M | — |
| Q4 2015 | 2015-12-31 | $19.9M | $13.7M | +218.17% |
| Q3 2015 | 2015-09-30 | −$575,000 | $4.1M | — |
| Q2 2015 | 2015-06-30 | $14.7M | $21.6M | — |
| Q1 2015 | 2015-03-31 | $503,000 | $19.6M | — |
| Q4 2014 | 2014-12-31 | $6.3M | $15.7M | — |
| Q3 2014 | 2014-09-30 | −$4.7M | $10.8M | — |
| Q2 2014 | 2014-06-30 | −$6.9M | $8.8M | — |
| Q1 2014 | 2014-03-31 | −$19.1M | −$1.9M | — |
| Q4 2013 | 2013-12-31 | −$9.4M | $6.7M | — |
| Q3 2013 | 2013-09-30 | −$15.6M | −$4.2M | — |
| Q2 2013 | 2013-06-30 | −$15.8M | −$6.1M | — |
| Q1 2013 | 2013-03-31 | −$17.2M | −$7.2M | — |
| Q4 2012 | 2012-12-31 | −$16.1M | −$7.9M | — |
| Q3 2012 | 2012-09-30 | −$11.3M | −$2.2M | — |
| Q2 2012 | 2012-06-30 | −$9.7M | −$665,000 | — |
| Q1 2012 | 2012-03-31 | −$10.1M | −$267,000 | — |
| Q4 2011 | 2011-12-31 | −$8.3M | — | — |
| Q3 2011 | 2011-09-30 | −$9.1M | — | — |
| Q2 2011 | 2011-06-30 | −$9.0M | — | — |
| Q1 2011 | 2011-03-31 | −$9.8M | — | — |
Supernus Pharmaceuticals operating cash flow trends
Over the last five fiscal years, Supernus Pharmaceuticals's operating cash flow decreased from $138.4M to $47.3M, a change of −$91.1M. The latest reported quarter, Q2 2026, shows −$4.8M.
About the metric
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
Calculation and source
SEC-reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Supernus Pharmaceuticals source filings ↗Community posts
Supernus and Indivior report sales growth ahead of their expected merger closing
Supernus ($SUPN) reported third-quarter 2026 revenue of $226.8 million, up 18%, with Qelbree sales increasing 12% to $90.8 million and Onapgo contributing $17.1 million. Separately, merger partner Indivior ($INDV) posted revenue of $356 mil ...
Supernus confirms ONAPGO exclusivity and seeks a second supplier
Supernus ($SUPN) said the FDA has recognized orphan-drug exclusivity for ONAPGO, its apomorphine infusion treatment for motor fluctuations in adults with advanced Parkinson's disease. The seven-year protection period runs from the medicine' ...
